Background: Gout, resulting from the precipitation of urate crystals in the tissues and the subsequent inflammatory response, causes an exquisitely painful distal monoarthritis alongwith joint destruction, subcutaneous deposits (tophi), renal calculi. The main culprit is uric Acid, which is a waste product formed due to purine metabolism. Gout Patients either produce excess Uric acid or are unable to excrete Uric acid produced in normal conditions. Uric acid lowering therapy (ULT) has become popular regarding management of gout. Nowadays. 2 drugs which are responsible for decreasing synthesis of Uric acid are Febuxostat and Allopurinol. The purpose of this study is to determine efficacy of Febuxostat and Allopurinol experienced by patients during course of therapy.Methods: It was an open, prospective, observational, non-invasive, parallel and randomised study, conducted at the Outpatient Department of Urology, Rajindra Hospital, Patiala. It had 60 patients of gout, out which, 30 patients were administered Febuxostat and 30 patients were administered Allopurinol. For each patient, history regarding drug intake was taken, along with analysis of Serum Uric acid profile before prescription and during follow up.Results: The mean age selected for study was 47 years for Febuxostat group and 43 years for Allopurinol group. Mean Urate (mg%) in pre-treatment stage of patients of Febuxostat group is about 8.28 whereas for Allopurinol group its about 8.61. Mean urate levels after 4 follow ups (10 days each) were conducted. The mean Urate level at 10, 20, 30, 40 days were conducted at each group which were found to be statistically significant and the results of Febuxostat group was found to be favourable.Conclusions: Febuxostat, (40mg) given at daily dose was found to have higher efficacy than allopurinol, at a dose of 100mg (zyloric) which is the most commonly prescribed dose in order to lower the serum urate level.
Histological prevalence of BPH alongwith LUTS was found to be 50% in men aged 50-60 years and of 90% over 80 years was seen. 75% of men above 50 years old had symptoms arising from BPH, and 20-30% of men reaching 80 years old required surgery.BPH being one of the commonest diseases to be managed by Urologists, its aetiology and pathophysiology are still unclear. 1 ABSTRACTBackground: Aim of the study was to compare efficacy of Tadalafil and Alfuzosin regimens in patients of Benign Prostate Hyperplasia. Methods: It was a comparative, prospective, observational, non-invasive, parallel and randomised study conducted at the Outpatient Department of Urology, Rajindra Hospital, Patiala. 60 patients diagnosed with Benign Prostate Hyperplasia along with Lower Urinary Tract Symptoms, out which, 30 patients, consuming Tadalafil and 30 patients consuming Alfuzosin were considered. History regarding the concerned disease and the compliance of treatment was taken. Symptom scores were assessed with the help of International Prostate Symptom Score, Quality of Lifestyle Score and Erectile Dysfunction Score. Physical examination consisting of Focused Neurological Examination along with Digital Rectal Examination were conducted. Parameters like Renal Function Test, Urine analysis, Ultrasound of Prostate and uroflowmetry were also considered.Results: The mean age selected for study was 64 years for Tadalafil and Alfuzosin group. The mean level of IPS Score, Qol Score and ED Score at the first day of inclusion of patients were 23.96±4.49, 4±0.78, and 25.33±4.02 respectively for Tadalafil group and regarding Alfuzosin group they were 25.23±4.84, 3.56±0.81, and 26.1±4.04 respectively. Follow ups were conducted at 15 days, 1 month and 3 months for both the groups which were found to be statistically significant after 3 months and Alfuzosin showed a favourable result. Conclusions: Alfuzosin 10mg given at daily dose was found to have higher efficacy than Tadalafil (5mg).
Designing of drugs and their development are a time and resource consuming process. There is an increasing effort to introduce the role of computational approach to chemical and biological space in order to organise the design and development of drugs and their optimisation. The role of Computer Aided Drug Designing (CADD) are nowadays expressed in Nanotechnology, Molecular biology, Biochemistry etc. It is a diverse discipline where various forms of applied and basic researches are interlinked with each other. Computer aided or in Silico drug designing is required to detect hits and leads. Optimise/ alter the absorption, distribution, metabolism, excretion and toxicity profile and prevent safety issues. Some commonly used computational approaches include ligand-based drug design, structure-based drug design, and quantitative structure-activity and quantitative structure-property relationships. In today's world, due to an avid interest of regulatory agencies and, even pharmaceutical companies in advancing drug discovery and development process by computational means, it is expected that its power will grow as technology continues to evolve. The main purpose of this review article is to give a brief glimpse about the role Computer Aided Drug Design has played in modern medical science and the scope it carries in the near future, in the service of designing newer drugs along with lesser expenditure of time and money.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.